News
A Common Weight Loss Drug Can Treat Severe Liver Disease, F.D.A. Says
The Food and Drug Administration approved the weight loss drug Wegovy to treat an increasingly prevalent liver disease on Friday. Roughly 15 million people — six percent of adults in the United States — have metabolic dysfunction-associated steatohepatitis, known as MASH. Rates of the disease are rising.
Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...
3hon MSN
Half-off Ozempic? US patients paying in cash can now buy the popular weight-loss drug for less
The drug is available as a weight-loss medication under the brand name Wegovy and will now also be sold directly to diabetes ...
Investor's Business Daily on MSN4h
Viking Therapeutics Crashes 35% On Mixed Results For Its Weight-Loss Pill
Viking Therapeutics stock crashed Tuesday — losing more than a third of its value — on mixed results for its weight-loss pill ...
U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...
GoodRx and Novo Nordisk launch a $499 monthly self-pay option for Ozempic and Wegovy, expanding access at 70,000 pharmacies across the U.S.
At least 500,000 people in the UK take either Mounjaro or Wegovy, another weight-loss jab, through private prescriptions ...
Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...
A sweeping analysis of global studies reveals that stopping weight loss drugs, including well-known treatments like Ozempic and Wegovy, often triggers a rapid return of lost pounds.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback